Business View Magazine | August 2020

11 BUSINESS VIEW MAGAZINE AUGUST 2020 Pollard and colleagues report their phase 1/2 randomized trial of one injection of chimpanzee adenovirus-vectored COVID-19 vaccine. Local and systemic adverse events such as fatigue, headache, and local tenderness occurred commonly in COVID-19 vaccines, but were tolerable and mostly ameliorated by paracetamol. No serious adverse events occurred. Chen and colleagues reported results from a phase 2 randomized trial of single-dose immunization schedule of Ad5-vectored COVID-19 vaccine. Most injection site and systemic solicited reactions from the participants in China were mild or moderate. Adverse reactions occurred in this study includes fever, fatigue, headache, and injection site pain. According to the comment article written by Professor Naor Bar-Zeev and Professor William J Moss, “Overall, the results of both trials are broadly similar and promising, notwithstanding differences in the vector, in the geographical locations of the populations studied, and the neutralization assays used. These COVID-19 vaccine trials are small, so inferential caution is warranted, but the explorations are laudable. Ethnic diversity in both these trials was very limited.” “Equal Global Access to COVID-19 Vaccine”: China and UK’s Common Goal and Commitment “It is good news,” Dr. Mike Ryan, Executive Director of the WHO’s emergencies program, said at a press conference at the organization’s OPENING L INES